semaj83/ctmatch_classification huggingface dataset:
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dyspnea Acute Heart Failure Shortness of Breath Age ≥ 18 years Presentation to the ED with undifferentiated shortness of breath  Dyspnea of obvious cause, e.g. chest trauma, obvious clinical exacerbation of known chronic obstructive disease Obvious pulmonary edema in a patient with a known diagnosis of HF and recently admitted to hospital for HF Clinician does not plan to treat for AHF at all, but rather to pursue other causes of dyspnea (i.e., probability of AHF ≤ 20%) Clinician plans to treat for AHF and not to pursue other causes of dyspnea (i.e., probability of AHF ≥ 80%) Acute coronary syndrome within one month Chronic renal failure (serum creatinine ≥ 250 mol/l) Anticipated life expectancy < 6 months due to non-cardiovascular causes Participation in another interventional outcome trial Inability to obtain informed consent, including inability of patient to understand English
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Asthma Patients Men and women. Women must be surgically sterilized/postmenopausal or use double barrier method contraception months history of asthma according to ATS definition Prescribed daily dose of ICS and LABA for at least 3 months prior to Visit 2 Pre-bronchodilator FEV1 of 40 to 85 % of predicted normal A total ACQ5 score of 1.5 or more  Respiratory infection significantly affecting the asthma Any significant disease and disorder that may put the patient at risk or influence study results Any clinically relevant abnormal findings A smoking history of more than 10 pack years Intake of oral, rectal or parenteral glucocorticosteroids
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Rhinitis, Allergic, Perennial Patient Current Seasonal Allergic Rhinitis sufferer (based on physician judgement) Currently receiving prescribed INS treatment (no other treatment restrictions apply) Have consumed at least one full prescription on the specified INS treatment No comorbid Asthma or COPD diagnosis Informed Consent  None specified
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Depression, Myalgia Capable of providing informed consent American Society Anesthesiologists (ASA) rating I-III Subjects age 18-80 capable of providing consent Subjects undergoing electroconvulsive therapy using succinylcholine as the sole neuromuscular blocking agent Subjects who have scored ≥23 on the Mini-Mental State Examination  Subjects who have had a recent thrombotic event, myocardial infarction or stroke or episode of Congestive Heart Failure (CHF) within less than 3 months Subjects who have had a recent cardiovascular surgery within the last 3 months Subjects with active Gastrointestinal bleeding Subjects who have asthma, itching or allergic type reaction following aspirin or other NSAID administration Subjects with a known hypersensitivity to ibuprofen Subjects with heart failure, bleeding disorders or kidney failure Subjects taking aspirin, Angiotensin converting enzyme (ACE) inhibitors, or anticoagulants within one month Subjects with any devices used to treat pain (intrathecal pumps, spinal cord stimulators etc) Subjects with a history of fibromyalgia or chronic myositis Subjects who are pregnant
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 3.0-999.0,  Collection of Clinical Data That Will be Used in This Study and Will Form a Data Bank for Asthma in Saudi Arabia Identify Known and NOVEL Genetic Risk Factors Contributing to Asthma Susceptibility Study the Mechanistic Roles of the Genetic Variants Within Major Asthma Susceptibility Genes Subjects with documented clinical history of asthma for a period of at least 6 months prior to study entry (and a minimum of one clinic follow-up visit since initial diagnosis) 2. Willing to provide written informed consent and in the judgment of the investigator, individuals who are able to understand the informed consent process. 3. Subjects with documented clinical history (in preceding 12 months) of airway reversibility of at least 12% based on Forced Expiratory Volume (FEV1), measured pre and post inhalation of a β-2 agonist (2 puffs of albuterol using a measured dose inhaler with spacer) OR 4. Individuals demonstrating airway 12% reversibility during recruitment testing and asthmatic symptoms, but with no prior history of asthma and not on an asthma treatment plan, can be recruited as affected individuals if in the opinion of the investigator the individuals are truly asthmatic and have no confounding factors that could explain the reversibility and symptoms. 7. Individuals with strong history of asthma but with waning, or no current symptoms may be included in the study if their asthma was well controlled using an asthma medication. Principal investigator must verify or know the clinical history of an individual before accepting him as an asthmatic individual. 8. Individuals with positive history of asthma but no asthma medication usage and with family history of asthma should be considered for as cases in the study only if other family members are being recruited. 9. Able to perform Spirometry/FEV1 correctly (only for those above 7years)  Age < 3 years 2. Smoking for 20 years, 1 pack/day or more. 3. Congestive heart failure. 4. COPD. 5. Chronic lung disease other than asthma and COPD. 6. Bronchiectasis
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Seasonal Allergic Rhinitis Subject is healthy History of seasonal allergic rhinitis Male aged between 18 and 55 years Body weight >/= 50 kg with BMI in range 19 kg/m2 (inclusive) Exhibits a moderate response to 4 hour exposure to grass pollen in the challenge chamber with a total nasal symptom score (TNSS) of >/= 6 Positive skin prick test (wheal >/= 4 mm) for grass pollen Positive total IgE result (RAST class >/= 2) for grass pollen Current non-smoker who has not used tobacco in the past 6 months with a pack history of </= 10 pack years Baseline FEV1 >/= 80% and FEV1/FVC >/= 70% of predicted values  structural nasal abnormalities or nasal polyps, history of frequent nosebleeds, recent nasal surgery or recent (within 3 weeks) or ongoing upper respiratory tract infection history of drug allergy participation in another clinical trial or has participated in a study using an NCE within the previous 3 months, or any clinical study within 1 month taking regular (or a course of) medication whether prescribed or not, including steroids, vitamins, macrolides, anti-fungal agents and herbal remedies. Paracetamol (</= 2g / day) and occasional short acting beta agonists are permitted use of oral, injectable or dermal steroids within 5 weeks or intranasal and/or inhaled steroids within 1 week of the screening visit past or present disease, which as judged by the investigator, may affect the outcome of the study regular consumption of > 21 units alcohol per week infected with Hepatitis B, Hepatitis C, or HIV virus current or chronic history of liver disease, or known hepatic or biliary abnormalities positive test for drugs of abuse or alcohol at screening
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Asthma Males and females, 18 to 65 years of age. 2. FEV1 60-85% of predicted on the screening day. -  Women of childbearing potential who do not use accepted birth control measures; pregnant and breast feeding women. 2. Cardiovascular disease and/or use of cardiovascular medications 3. Subjects with known beta-adrenergic agonist or glucocorticosteroid intolerance 4. Acute respiratory infection within four weeks prior to the study 5. Use, within two weeks prior to the study, of any anti-asthma medication not mentioned above -
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 12.0-70.0,  Asthma Provision of informed consent by the subject and his/her legal guardian if the subject is under 18 years old Male or females aged more than 12 and under 70 Had a definite diagnosis of asthma with symptoms of cough/expectoration/chest tightness/wheeze/breathlessness within the last one month Inhaled corticosteroid (ICS) naïve or no regular use of ICS within the last one month (It is suggested that ICS average daily dose with no more than 100mg budesonide or equal within the last month as "No-regular-use") FEV1 between 60% and 85% of predicted normal values Reversibility test of airway obstruction is positive, i.e. degree of reversibility in FEV1 as over 12%(included) and 200ml(included). Or average diurnal PEFR variability is not less than 20% in two weeks Are able to use Peak Flow Meter and record it on patient diary card  Asthma exacerbation leading to hospitalization for more than 2 days within the last 6 months or emergency room visit due to asthma exacerbation in the last 3 months prior to screening Infection of respiratory system in the last 4 weeks prior to screening visit Use of oral, injectable, rectal or transdermal glucocorticoid in the last 4 weeks prior to screening visit Use of Leukotriene receptor antagonist (LTRAs), oral b2 agonist, methylxanthines or use of inhaled long acting b2 agonist, inhaled anticholinergic receptor in the last 1 week, or inhaled Tiotropium Bromide within 45 days prior to screening visit Patients with chronic obstructive pulmonary disease (COPD)or COPD with asthma Patients with severe persistent asthma (Based on definition in GINA 2006) Patients with specific immunity treatment (including monoclonal antibody treatment) due to asthma within the 6 months prior to screening visit Patients with eye disorders including cataract, glaucoma and herpes virus infection Smoking history of 10 pack-year (1 pack-year refers to 20 cigarette per day for 1 year) History of drug or alcohol abuse
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 16.0-49.0,  Persistent Cough Whooping Cough Male or Female, aged 16 years to 49 years inclusive Presenting with a persistent cough of 2-8 weeks' duration without an established diagnosis (e.g. asthma, gastro-oesophageal reflux) Able to complete cough diary and study questionnaires  There is a contraindication to montelukast Chronic severe disease which may cause persistent cough (eg cystic fibrosis, bronchiectasis, cardiac failure) Immunodeficiency/immunocompromised state Pregnancy Breastfeeding Current smoker (i.e. stopped smoking less than 6 months ago) Regular medication associated with persistent cough (ACE inhibitors) The individual is in another clinical research study
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Asthma all with asthma diagnosis  none
Patient description: A 39-year-old man came to the clinic with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week. He is a chef with a history of asthma for 3 years, suffering from frequent cough, wheezing, and shortness of breath and chest tightness. The symptoms become more bothersome within 1-2 hours of starting work every day and worsen throughout the work week. His symptoms improve within 1-2 hours outside the workplace. Spirometry was performed revealing a forced expiratory volume in the first second (FEV1) of 63% of the predicted. His past medical history is significant for seasonal allergic rhinitis in the summer. He doesn't smoke or use illicit drugs. His family history is significant for asthma in his father and sister. He currently uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg, one puff twice daily.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Asthma A clinical diagnosis of persistent mild to moderate asthma requiring at least 3 months of daily treatment with inhaled corticosteroids (ICS). 2. A FEV1 value at Screening that is 60-90% of predicted FEV1. 3. Age 18 to 65, males or females  Diagnosis or presence of other pulmonary diseases including chronic obstructive pulmonary disease (COPD) and emphysema. 2. Previous life-threatening asthma, such as asthma requiring intubation or ICU admission for asthma. 3. Prolonged hospitalization for asthma within the past year (emergency room treatments using nebulized beta-agonists is permitted). 4. Not able and willing to stop the use of long-acting beta-agonists (LABAs), cromolyn sodium, methylxanthines, anticholinergic agents, leukotriene inhibitors, or any other non-ICS or non-SABA prescription or over-the-counter anti-asthma medication, including antihistamines, during Screening and during the Study. 5. Use of moderate to strong cytochrome P450 3A4 (CYP3A4) inhibitors. 6. Use of oral steroids within the last 1 month, or use of >/= 3 steroid bursts in the last 12 months. 7. History of upper respiratory tract infection (URI) requiring treatment during the last month prior to Screening. 8. Tobacco use within 3 months prior to Screening, or > 5 pack-year lifetime tobacco use. 9. Use of smoking cessation therapy within 3 months prior to Screening. 10. Uncontrolled Gastroesophageal reflux disease (GERD). Subjects on a stable dose of non-prescription or prescription medications who have been symptom free for 4 wks prior to screening are eligible. 11. History within past 6 months of alcohol abuse or illicit drug abuse. 12. Myocardial infarction within 12 months prior to Screening. 13. Known hypothyroidism, vitamin B12, or folic acid deficiency. 14. Known systemic infection (HBV, HCV, HIV, TB). 15. FSH level of < 35 IU/L and a LH level < 25 IU/L. 16. Urine cotinine level > 50 ng/ml. 17. Body Mass Index (BMI) <15 and >35. 18. Participation in another clinical trial in the past 3 months